Advances in Alcohol Use Disorder Treatment
- 1st Edition, Volume 178 - November 12, 2024
- Editors: Rosana Camarini, Fabio Cardoso Cruz
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 6 3 8 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 6 3 9 - 0
Advances in Alcohol Use Disorder Treatment, Volume 178 in the International Review in Neurobiology series, presents a comprehensive exploration of emerging therapies and approa… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote- Explores neurobiological, pharmacological, and unconventional modalities for treating AUD
- Integrates insights from leading experts, bridging pre-clinical and clinical viewpoints
- Investigates new compounds and cutting-edge research in AUD treatment
Researchers and Academics in Addiction, Clinicians and Healthcare Professionals Specializing in Substance Use Disorders, Psychologists and Psychiatrists, Professionals and Scholars in Neurobiology, Students and Graduates in Medicine and Pharmacology, Public Health Practitioners Focused on Addiction, Policy Makers in the Field of Substance Abuse, Those Interested in Cutting-Edge Approaches to Alcohol Use Disorder Treatment
- Title of Book
- Cover image
- Title page
- Table of Contents
- Series Page
- Copyright
- Contributors
- Preface
- Chapter One: Introduction: Approved treatments for alcohol use disorder by regulatory agencies
- Abstract
- 1 Introduction
- 2 Genetic variability and drug responses
- 3 Approved treatments
- 4 Final considerations
- References
- Chapter Two: Role of oxytocin and vasopressin in alcohol use disorder
- Abstract
- 1 Introduction
- 2 The oxytocin system
- 3 The vasopressin (VP) system
- 4 Discussion
- Acknowledgments
- References
- Chapter Three: Emerging evidence for pregnane steroid therapeutics for alcohol use disorders
- Abstract
- 1 Introduction
- 2 Pregnane neurosteroid biosynthesis and modes of action
- 3 Neurobiological basis of AUDs
- 4 Pregnane steroids mitigate neurobiological adaptations in AUD
- 5 Potential benefits of pregnane steroid replacement in AUD
- 6 Potential limitations of pregnane steroid therapeutics
- 7 Potential interactions with other drugs of abuse
- 8 Challenges in the development of pregnane steroid therapeutics
- 9 Conclusions
- References
- Chapter Four: The CRF/Urocortin systems as therapeutic targets for alcohol use disorders
- Abstract
- 1 Overview
- 2 Corticotropin-releasing factor (CRF) and CRF family peptides: an overview
- 3 Alcohol exposure impacts CRF/Urocortins signaling
- 4 Pharmacological manipulations of CRF/Ucn targets in preclinical models of alcohol use disorders
- 5 Therapeutic interventions and human studies with CRF/Ucn targets
- 6 Summary and perspectives
- References
- Chapter Five: Pharmacological activators of ALDH2: A new strategy for the treatment of alcohol use disorders
- Abstract
- 1 Introduction
- 2 Ethanol metabolism
- 3 ADH and ALDH polymorphisms
- 4 Inhibitors of ALDH2 in the treatment of alcoholism
- 5 Acetaldehyde is a central rewarding metabolite of ethanol
- 6 Alda-1, a pharmacological activator of ALDH2
- 7 Effects of Alda-1 in animal models of alcohol preference
- 8 Future directions for ALDH2 activators
- 9 Conclusions
- Acknowledgments
- References
- Chapter Six: Mesenchymal stem cells as a promising therapy for alcohol use disorder
- Abstract
- 1 Introduction
- 2 Alcohol use disorder
- 3 Glutamatergic pathways as major inducers of ethanol consumption
- 4 Modulation of GLT1 expression as therapy for the alcohol use disorder
- 5 Contribution of oxidative stress and neuroinflammation to the mechanism of ethanol consumption
- 6 Anti-inflammatory and antioxidant therapies to reduce ethanol consumption
- 7 Mesenchymal stem cells as potential antioxidant and anti-inflammatory therapy for addressing AUD
- 8 Preclinical evidence of the use of mesenchymal stem cells to reduce ethanol consumption
- 9 Secretome derived from mesenchymal stem cells as an improved antioxidant and anti-inflammatory biodrug
- 10 Therapeutic potential of MSCs secretome in the treatment of alcohol use disorder
- 11 Conclusion
- Acknowledgment
- References
- Chapter Seven: Sodium oxybate: A comprehensive review of efficacy and safety in the treatment of alcohol withdrawal syndrome and alcohol dependence
- Abstract
- 1 Introduction
- 2 History of sodium oxybate
- 3 Sodium oxybate clinical pharmacology
- 4 Efficacy of SMO in the treatment of AWS
- 5 Efficacy of SMO in maintenance of abstinence
- 6 Safety of SMO in the treatment of AD
- 7 Benefit-risk ratio of SMO in the treatment of AD
- References
- Chapter Eight: Ayahuasca for the treatment of alcohol use disorder
- Abstract
- 1 Psychedelics
- 2 Psychedelics for the treatment of AUD
- 3 Ayahuasca
- 4 Ayahuasca for the treatment of AUD
- References
- Chapter Nine: Cannabinoid for alcohol use disorder
- Abstract
- 1 Introduction
- 2 Concluding remarks
- References
- Chapter Ten: Environmental enrichment and complementary clinical interventions as therapeutic approaches for alcohol use disorder in animal models and humans
- Abstract
- 1 Alcohol use disorder: a multifactorial disorder
- 2 Environmental enrichment: history, concepts, and neurobiological effects
- 3 The impact of environmental enrichment on multiple alcohol-induced behaviors and its mechanisms
- 4 Physical activity as environmental enrichment
- 5 Translational implications: complementary clinical interventions as environmental enrichment in AUD
- References
- Chapter Eleven: Animal models for studying therapeutic targets and treatments for alcohol use disorder
- Abstract
- 1 Introduction
- 2 Conditioned place preference
- 3 Non-operant alcohol self-administration models
- 4 Operant alcohol self-administration
- 5 Chronic intermittent ethanol vapor exposure
- 6 Others useful procedures
- 7 Concluding remarks
- References
- Further reading
- Chapter Tweleve: GABAergic compounds for the treatment of alcohol use disorder
- Abstract
- 1 GABAA compounds
- 2 GABAB compounds
- 3 Conclusions
- Acknowledgements
- References
- Chapter Thirteen: Ghrelin system and GLP-1 as potential treatment targets for alcohol use disorder
- Abstract
- Abbreviations
- 1 Gut–brain axis
- 2 Summary and future directions
- Acknowledgment
- References
- No. of pages: 454
- Language: English
- Edition: 1
- Volume: 178
- Published: November 12, 2024
- Imprint: Academic Press
- Hardback ISBN: 9780443296383
- eBook ISBN: 9780443296390
RC
Rosana Camarini
Rosana Camarini is an Associate Professor and Principal Investigator at the Universidade de São Paulo, Brazil, specializing in neuropsychopharmacology with a focus on the neurobiological basis of drug addiction and dependence. With a Ph.D. from Universidade Federal de São Paulo and postdoctoral training at Ernest Gallo Clinic and Research Center, UCSF, her academic journey has been marked by a commitment to understanding the interplay between early drug exposure, environmental stimuli, and addictive behaviors, with focus on drug addiction. Additionally, she has served as a Visiting Professor at Medical University of South Carolina, Charleston, USA, Arizona State University, Tempe, USA, and Sorbonne Université, Paris, France, enriching her academic experience and fostering international collaborations. Throughout her career, Camarini has explored the behavioral and neurochemical/molecular effects of alcohol and cocaine exposure during early drug exposure, particularly during prenatal and adolescent stages. Moreover, she has investigated the impact of environmental enrichment/exercise on addiction, highlighting its potential as a non-pharmacological intervention. Camarini served as President of the International Society for Biomedical Research on Alcoholism (ISBRA), from 2020-2022, where she spearheaded initiatives promoting diversity and early career development. Additionally, her role in revitalizing the Latin American Society for Biomedical Research on Alcoholism (LASBRA) underscores her dedication to regional scientific advancement. Camarini has chaired and given lectures at numerous international symposia, contributing to the global discussion on addiction research. In addition to her academic pursuits, Camarini holds key administrative roles, including Head of the Pharmacology Department and Coordinator of the Neuroscience Research Support Center at Universidade de São Paulo, Brazil (USP). Her commitment to scientific rigor is evident through her involvement in “Experimental Planning and Reproducibility Strategies Core” of the Institute of Biomedical Sciences at USP. With over 100 publications indexed in PubMed, she has a plethora of ongoing research projects funded by prestigious Brazilian agencies like FAPESP (The State of Sao Paulo Research Agency) and CNPq (National Council for Scientific and Technological Development). Camarini's contributions also extend to serving as an editor and editorial board member for addiction journals. Through her mentorship of graduate students and postdocs, she nurtures the next generation of scientists, ensuring a legacy of excellence in neuropsychopharmacology research.
FC
Fabio Cardoso Cruz
His research extends to investigating sex differences in responses to drugs and stress, as well as understanding the long-term consequences of early drug exposure on brain function, escalating the risk of addiction. Utilizing an innovative combination of optogenetic and chemogenetic tools alongside transgenic rodent models, Cruz and his team have made significant strides in shedding light on the biological underpinnings of addiction behaviors.
Moreover, Cruz has expanded his research into proteomics, delving into metabolomics and transcriptomics of single cells. His utilization of sophisticated techniques such as immunohistochemistry, fluorescence, FACS, and western blotting has been pivotal in advancing the understanding of addiction.
In the realm of animal models, Cruz has employed operant self-administration, the ABA renewal, and conditioning place preference paradigms to gain insights into addiction behaviors. This comprehensive methodological approach underscores his commitment to cutting-edge research and addressing the complexities of drug use disorders.
Driven by an insatiable curiosity and a profound dedication to contributing meaningful insights, Fábio Cardoso Cruz aims not only to advance the scientific community's understanding of addiction but also to pave the way for the development of more effective interventions. Through his research and mentorship, he aspires to inspire the next generation of scientists to explore the uncharted frontiers of neuropsychopharmacology.